Nadia Magdalinou

National Hospital for Neurology and Neurosurgery — United Kingdom

Medicine · Health Sciences

18h-index3.0kcitations36works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(18), Alzheimer's disease research and treatments(14), Neurological disorders and treatments(11), Dementia and Cognitive Impairment Research(10), Neurological diseases and metabolism(5)

Publications36 total

Acquired comedonal plaques in a middle-aged woman
Clinical and Experimental Dermatology·2024
Corrigendum to “Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease” [Clin. Mass Spectrom. 14 (Part B) (2019) 74–82]
Journal of Mass Spectrometry and Advances in the Clinical Lab·2022Open Access
Diagnostics in Neurodegenerative Parkinsonism
UCL Discovery (University College London)·2020
Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease
Clinical mass spectrometry·2019· 18 citedOpen Access
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology
JAMA Neurology·2019· 728 citedOpen Access
Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes
Journal of Neurology Neurosurgery & Psychiatry·2019· 59 citedOpen Access
Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate
Neurocase·2018· 25 citedOpen Access
O3‐14‐04: THE PROTEIN‐TO‐PEPTIDE RATIO IMPROVES THE PERFORMANCE OF MICROTUBULE‐ASSOCIATED PROTEIN TAU IN CSF AS AN ALZHEIMER BIOMARKER
Alzheimer s & Dementia·2018
Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic
Alzheimer s Research & Therapy·2018· 129 citedOpen Access
CSF neurogranin or tau distinguish typical and atypical Alzheimer disease
Annals of Clinical and Translational Neurology·2018· 35 citedOpen Access
[O4–02–01]: PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON's AND ALZHEIMER's DISEASE
Alzheimer s & Dementia·2017· 1 cited
Blood-based NfL
Neurology·2017· 469 citedOpen Access
Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics
Parkinsonism & Related Disorders·2017· 50 citedOpen Access
Clinical Features and Differential Diagnosis of Parkinson’s Disease
2017· 9 cited
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer’s disease pathology
Translational Psychiatry·2016· 67 citedOpen Access
O4‐10‐01: PLASMA NFL: A NEW BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN DISORDERS
Alzheimer s & Dementia·2016
O1‐11‐05: CSF In the Differential Diagnosis of Alzheimer's Disease: Clinical Utility of an Extended Panel Of Biomarkers in a Specialist Cognitive Clinic
Alzheimer s & Dementia·2016· 1 cited
Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
Molecular Neurodegeneration·2016· 3 citedOpen Access
Increased CSF neurogranin concentration is specific to Alzheimer disease
Neurology·2016· 246 citedOpen Access
Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids
ACS Chemical Neuroscience·2016· 118 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Henrik Zetterberg(24), Jonathan M. Schott(19), Kaj Blennow(18), Ross W. Paterson(18), Nick C. Fox(14), Andrew J. Lees(10), Jamie Toombs(7), Oskar Hansson(6), Amanda Heslegrave(6), Huw R. Morris(6), Catherine F. Slattery(6), Jason D. Warren(6), Ulf Andréasson(5), Wendy Heywood(5), Kevin Mills(5), Catherine J. Mummery(5), Thomas T. Warner(5), Michael P. Lunn(5), Jennifer M. Nicholas(4), Martin N. Rossor(4)